Compare Amgen, Inc. (AMGN) vs Open Text Corporation (OTEX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Open Text Corporation — how do they compare? Amgen, Inc. trades at $416.97 (market cap $224.14B), while Open Text Corporation trades at $23.72 (market cap $5.80B). The key difference: Amgen, Inc. is far larger — about 38.6× Open Text Corporation's market cap, and Open Text Corporation pays the higher dividend (4.67%). Which is the better fit depends on your goals.
| AMGN | OTEX | |
|---|---|---|
Market Cap | $224.14B | $5.80B |
Sector | Health | Technology |
52-Week High | $417.20 | $39.69 |
52-Week Low | $271.18 | $20.01 |
Enterprise Value | $267.45B | $10.81B |
Dividend Yield | 2.43% | 4.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amgen (AMGN) trades at $416.74, showing minimal daily movement with a slight 0.11% decline. The stock maintains strong technical momentum with bullish moving averages and support at $412. Fundamentally, the company demonstrates robust performance with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, while revenue growth continues with 2025 revenue reaching $36.75 billion. Analyst sentiment remains positive with 59% buy ratings, though the current price exceeds the consensus target of $394.69.
Amgen presents a mixed outlook with strong earnings momentum and product growth offset by valuation concerns. Investment opportunities include continued blockbuster drug performance and raised 2026 guidance, while risks involve high debt levels and potential data breach litigation impacts. The stock's current premium valuation requires sustained execution to justify further upside.
Open Text Corporation (OTEX) trades at $23.62, down 4.45% in the past 24 hours, with a bullish technical signal despite bearish moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.23 exceeding expectations. Valuation metrics appear attractive with a P/E of 9.29 and EV/EBITDA of 5.95, while profitability remains solid with a net income margin of 12.26% and ROE of 16.19%.
The outlook is positive given consistent earnings outperformance and a consensus price target of $29.33, implying 24% upside. Risks include high debt levels and competitive pressures in the software sector. Investor sentiment is mixed, with analysts showing cautious optimism amid recent institutional selling.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Open Text Corporation
Open Text Corporation is a global leader in Enterprise Information Management (EIM) software and solutions. The company provides a comprehensive platform that helps organizations manage, secure, and leverage their unstructured digital content, including documents, emails, and media files. OTEX's offerings span content management, business process management, customer experience management, and security, serving large enterprises across various industries worldwide.
Read more on OTEX →
